Celcuity Inc. CELC
We take great care to ensure that the data presented and summarized in this overview for Celcuity Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CELC
View all-
Bvf Inc San Francisco, CA3.47MShares$39.1 Million1.7% of portfolio
-
Baker Bros. Advisors LP New York, NY2.68MShares$30.2 Million0.39% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.57MShares$28.9 Million2.34% of portfolio
-
Perceptive Advisors LLC New York, NY2.36MShares$26.6 Million1.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.65MShares$18.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.46MShares$16.4 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA1.27MShares$14.3 Million0.32% of portfolio
-
Samlyn Capital, LLC New York, NY1.25MShares$14.1 Million0.26% of portfolio
-
Nea Management Company, LLC Timonium, MD1.25MShares$14.1 Million1.17% of portfolio
-
Saturn V Capital Management LLC Austin, TX1.06MShares$12 Million5.45% of portfolio
Latest Institutional Activity in CELC
Top Purchases
Top Sells
About CELC
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at CELC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 14
2025
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Direct |
8,155
+0.64%
|
-
|
|
Apr 14
2025
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
8,155
-100.0%
|
-
|
|
Mar 04
2025
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
36,845
+4.39%
|
-
|
|
Mar 04
2025
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
36,845
-81.88%
|
-
|
|
Mar 03
2025
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
84,670
+27.01%
|
-
|
|
Mar 03
2025
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
84,670
-3.2%
|
-
|
|
Dec 02
2024
|
Leo Furcht |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+2.27%
|
$750
$3.6 P/Share
|
|
Oct 23
2024
|
Richard E Buller Director |
SELL
Open market or private sale
|
Indirect |
350
-4.98%
|
$5,600
$16.25 P/Share
|
|
Aug 23
2024
|
Richard E Buller Director |
SELL
Open market or private sale
|
Indirect |
350
-4.74%
|
$5,600
$16.95 P/Share
|
|
Aug 20
2024
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Direct |
189,103
+12.35%
|
-
|
|
Aug 20
2024
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
189,103
-100.0%
|
-
|
|
Jun 21
2024
|
Richard E Buller Director |
SELL
Open market or private sale
|
Indirect |
350
-4.53%
|
$5,250
$15.68 P/Share
|
|
Jun 10
2024
|
Richard Nigon Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
5,061
+4.77%
|
$45,549
$9.5 P/Share
|
|
Jun 04
2024
|
Richard E Buller Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,079
+13.6%
|
-
|
|
May 22
2024
|
Richard E Buller Director |
BUY
Bona fide gift
|
Indirect |
1,958
+50.0%
|
-
|
|
May 22
2024
|
Richard E Buller Director |
SELL
Bona fide gift
|
Direct |
1,958
-25.33%
|
-
|
|
Apr 26
2024
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
45,025
+4.72%
|
-
|
|
Apr 26
2024
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
45,025
-3.76%
|
-
|
|
Apr 24
2024
|
Richard E Buller Director |
SELL
Open market or private sale
|
Direct |
350
-4.33%
|
$5,950
$17.06 P/Share
|
|
Mar 18
2024
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
765,897
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.08K shares |
|---|---|
| Bona fide gift | 321K shares |
| Exercise of in-the-money or at-the-money derivatives securities | 5.06K shares |
| Exercise of conversion of derivative security | 250 shares |
| Bona fide gift | 321K shares |
|---|---|
| Open market or private sale | 1.05K shares |